Meeting
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
Authors
Krish Patel
Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA
Krish Patel , Sarah Rothman , Poulomee A Das , Stephanie Yee , Indu Ramachandran , Iphigenia Koumenis , Terry A Cook , Ying Yuan , Nikolaus S. Trede , Ahmad Hatem Mattour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05336409
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7580)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7580
Abstract #
TPS7580
Poster Bd #
130a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.
First Author: Amrita Y. Krishnan
Poster
2018 ASCO Annual Meeting
Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.
First Author: Toshio Kubo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of an all-in-one 5-fluorouracil and leucovorin co-formulation administered after failure of standard treatment.
First Author: Daniel Brungs
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess